Phase 2 study of Nab-Paclitaxel for patients with previously treated EGFR wild-type non-small-cell lung cancer.

Phase 2 study of Nab-Paclitaxel for patients with previously treated EGFR wild-type non-small-cell lung cancer. - Phase 2 study of Nab-Paclitaxel for patients with previously treated EGFR wild-type non-small-cell lung cancer.

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000018233

Enrollment

Registered

2015-07-07

Start date

2013-10-28

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-small-cell lung cancer

Interventions

Nab-Paclitaxel

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Histologically or cytologically confirmed non-small-cell lung cancer and unresectable or postoperative recurrence NSCLC 2)Measurable lesions 3)Preceding anticancer agent treatment was provided and was taken as PD 4)ECOG PS 0-2 5)Adequate function of main organ 6)Do not have peripheral neuropathy, or cases less than G1 7)Provided written informed consent

Exclusion criteria

Exclusion criteria: 1)Brain metastasis with the symptom 2)Active interstitial pneumonia or pulmonary fibrosis 3)Body fluid retention to need waste fluid 4)Hypersensitivity for paclitaxel or albumin 5)Pregnant or nursing female or man without the intention of the contraception 6)Active concomitant malignancy 7)Inappropriate patients for this study judged by the physicians

Design outcomes

Primary

Measure	Time frame
responce rate	—

Secondary

Measure	Time frame
adverse event, QOL, Dose intensity	—

Countries

Japan

Contacts

Public ContactHamaguchi Megumi

Shimane university hospital Clinical oncology and Respiratory medicine

hs1219@med.shimane-u.ac.jp0853-20-2580

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026